The Clinical and Laboratory Standards Institute announces the publication of new antimicrobial susceptibility testing documents CLSI M100-Ed34, M02-Ed14, and M07-Ed12

April 11, 2024
CLSI update.

The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition.

The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures defined in CLSI standards CLSI M02, M07, and M11, which cover the most up-to-date recommended methods for susceptibility testing and quality control.

With the new document updates this year, CLSI is offering its customers the following package pricing:

CLSI M02 + CLSI M100 Package in Print
CLSI M02 + CLSI M100 Package in Electronic Format (PDF)

CLSI M07 + CLSI M100 Package in Print
CLSI M07 + CLSI M100 Package in Electronic Format (PDF)

CLSI M100 + CLSI M02 + CLSI M07 Package in Print
CLSI M100 + CLSI M02 + CLSI M07 Package in Electronic Format (PDF)

In addition, CLSI will host its annual What’s New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing webinar hosted by Janet Hindler, MCLS, MT(ASCP), F(AAM), of the Los Angeles Department of Public Health. The webinar will include laboratory experts Romney M. Humphries, PhD, D(ABMM) of Vanderbilt University and April M. Bobenchik, PhD, D(ABMM), MT(ASCP), of Penn State Health and Milton S. Hershey Medical Center.

The webinar is designed to help users identify the major changes in the new editions, learn implementation strategies, and suggest communication approaches for informing clinical staff about the significant AST and reporting changes. Some of the major updates that will be discussed during the webinar include:

  • A significant reorganization of dosage recommendations.
  • The addition of sulbactam-durlobactam to breakpoints.
  • A new Table 2A-2 for Salmonella and Shigella.

Substantive changes to CLSI M02 and CLSI M07 will also be discussed. The webinar will take place on April 17, 2024 from 1:00-2:30 PM ET.

CLSI release

Photo 111134338 © Kwanchaidt |
Photo 81363766 © Andrii Kucher |
Photo 125378010 © Komgrit Pradissagul |
Photo 36810879 © Tyler Olson |